AUDIOCURE-PHARMA-GMBH
22.5.2017 13:14:11 CEST | Business Wire | Press release
AudioCure, a German pharmaceutical company focusing on the development of treatments for hearing disorders, announced today that it has appointed Dr. Reimar Schlingensiepen as CEO.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170522005541/en/
Dr. Schlingensiepen has been with AudioCure as COO since July 2015. During that time, he has successfully reshaped the company and carved out the recent series A financing round of about 9 million euros. He takes over from Prof. Hans Rommelspacher, who will continue as CSO. “With Reimar´s deep commitment to AudioCure, his proven track record and over 20 years of experience in the biopharmaceutical industry spanning preclinical, clinical and product development, I could not have wished for a better person for the job of CEO,” said Prof. Rommelspacher.
Since 2008, Dr. Schlingensiepen has worked as entrepreneur and manager in the fields of biopharmaceutical development, med-tech and diagnostics. He co-founded a number of high-tech companies, where he held several management positions. In addition to his leadership and biopharmaceutical expertise, he brings to AudioCure substantial experience in manufacturing, marketing and finance. It is of great advantage to AudioCure that, as a medical doctor, Dr. Schlingensiepen also conducted a variety of clinical trials in oncology, immunology and neurology.
With AudioCure, Dr. Schlingensiepen´s immediate goal is to steer the company’s first in class front-runner molecule AC102 through its formal preclinical development. This is a prerequisite for the clinical development, which is planned in patients with auditory disorders including acute hearing loss and acute tinnitus.
“With the proof of principle for AC102 accomplished under the leadership of Prof. Rommelspacher, this is an exciting time in AudioCure’s development. We hold a gem in our hands with enormous potential for patients suffering from auditory disorders,” said Dr. Schlingensiepen. “In sharing responsibilities, Hans and I can continue on our seamless path to the clinic. I am very much looking forward to leading an AudioCure team that recognizes the unique opportunity we have to help transform the treatment landscape for hearing impairments.”
For further information: www.audiocure.de .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005541/en/
Contact:
AudioCure Pharma GmbH
Frauke Luers
Phone: +49 30 2218 39714
E-Mail:
pr@audiocure.de
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
IFF Declares Dividend for Second Quarter 202629.4.2026 22:25:00 CEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 10, 2026 to shareholders of record as of June 18, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260429658065/en/
Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn29.4.2026 20:25:00 CEST | Press release
Strong performance reflects sustained upward momentum driven by international expansion and operational efficiencyDigital transformation initiatives in automation and artificial intelligence enhanced productivity, governance, and cost optimization Estithmar Holding Q.P.S.C. announced its financial results for the first quarter of 2026, reporting a net profit of QAR 333 million, marking a significant 97% increase compared to the same period last year. The results underscore the strength of the Company’s operating model and the successful execution of its expansion strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429718889/en/ Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn (Photo: AETOSWire) The company recorded revenues of QAR 1.455 billion, up from QAR 1.309 billion in Q1 2025. Gross profit rose to QAR 561 million compared to QAR 416 million, representing a year-on-year increase of
DC Secretary Announces Annual Determinations Committees Outcome29.4.2026 15:36:00 CEST | Press release
DC Administration Services, Inc. has today announced the composition of five regional Determinations Committees (DCs), effective from April 29, 2026. Global Dealer Voting Members (for all Regions): Non-Dealer Voting Members (for all Regions): Bank of America, N.A. Citadel Americas LLC Barclays Bank plc Elliott Investment Management L.P. BNP Paribas Pacific Investment Management Company LLC Citibank, N.A. Deutsche Bank AG Goldman Sachs International JPMorgan Chase Bank, N.A. Regional Dealer Voting Member for the Americas, EMEA, Asia Ex-Japan, and Japan Determination Committees: CCP Members for the Americas, EMEA, Asia Ex-Japan, and Australia-New Zealand Determinations Committees: Mizuho Securities Co., Ltd. ICE Clear Credit LLC LCH S.A. The process for selecting DC members is specified in the DC rules. The DC rules, along with more information about the Determinations Committees and what they do can be found at the Determinations Committees website: https://www.cdsdeterminationscommitte
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom